End of Compounded Semaglutide; 464M Teens Will Have Obesity; GLP-1 Scripts Skyrocket

(MedPage Today) -- A federal deadline ending the sale of compounded semaglutide (Ozempic, Wegovy) is now in effect after a similar one for tirzepatide (Mounjaro, Zepbound) passed in March. (U.S. News & World Report)
A patient-delivered lifestyle...